Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.28 USD | -5.84% | -5.69% | -25.54% |
12:19am | Zentalis Says Azenosertib Combo Shows 'Promise' in Relapsed Osteosarcoma Trial | MT |
May. 08 | Stifel Adjusts Price Target on Zentalis Pharmaceuticals to $32 From $36, Maintains Buy Rating | MT |
Evolution of the average Target Price on Zentalis Pharmaceuticals, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Zentalis Pharmaceuticals, Inc.
Stifel Nicolaus | |
Wedbush | |
UBS | |
Morgan Stanley | |
HC Wainwright | |
Wells Fargo Securities | |
Jefferies & Co. | |
Guggenheim | |
SVB Securities LLC | |
Oppenheimer | |
Cowen | |
SVB Leerink |
EPS Revisions
- Stock Market
- Equities
- ZNTL Stock
- Consensus Zentalis Pharmaceuticals, Inc.